Immunic (IMUX) reported a net loss of $42.3 million, or $0.99 per basic and diluted share, for the third quarter ended September 30, 2026. The company held $132.0 million in cash and cash equivalents at quarter-end and said the funds are expected to support operations into late 2027.
The company said top-line data from its Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing multiple sclerosis remain expected in December 2026. Initiation of the Phase 3 PROTECT-MS trial in progressive multiple sclerosis is ongoing, with first-patient enrollment expected in the first half of 2027.
- Third-quarter operating expenses were $43.4 million, including $23.9 million in research and development expense and $19.4 million in general and administrative expense.
- Nine-month net loss was $109.0 million, or $2.83 per basic and diluted share.
- ENSURE-1 and ENSURE-2 randomized 1,121 and 1,100 patients, respectively, across more than 100 sites in 15 countries.
- If ENSURE results are positive, Immunic plans a U.S. NDA submission in mid-2027, with a targeted potential approval date in 2028.
$IMUX Hedge Fund Activity
We have seen 36 institutional investors add shares of $IMUX stock to their portfolio, and 44 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BRAIDWELL LP added 645,010 shares (+inf%) to their portfolio in Q2 2026, for an estimated $9,913,803
- AVIDITY PARTNERS MANAGEMENT LP added 602,947 shares (+900.0%) to their portfolio in Q2 2026, for an estimated $9,267,295
- JONES HILL CAPITAL LP added 539,814 shares (+inf%) to their portfolio in Q2 2026, for an estimated $8,296,941
- WOODLINE PARTNERS LP added 374,813 shares (+387.5%) to their portfolio in Q2 2026, for an estimated $5,760,875
- MILLENNIUM MANAGEMENT LLC added 362,355 shares (+95.9%) to their portfolio in Q2 2026, for an estimated $5,569,396
- MORGAN STANLEY removed 305,106 shares (-92.8%) from their portfolio in Q2 2026, for an estimated $4,689,479
- JANE STREET GROUP, LLC added 124,476 shares (+138.8%) to their portfolio in Q3 2026, for an estimated $1,157,626
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.